KURA
Kura Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.05
−18.52%Research · Aug 25, 2026
Menin Inhibitor Use Shifts Toward Off-Label Combination Regimens
Kura and Syndax each report about 40% of menin inhibitor use in physician-led combinations, moving the revenue variable to treatment duration rather than the label.